Cabot CORP
Market Movers (8-K)
NYSE
CBT
Cabot CORPCabot Corporation reported third quarter fiscal year 2026 results with diluted EPS of $0.12 and adjusted EPS of $1.67, driven by strong Performance Chemicals segment performance, while facing challenges in Reinforcement Materials.
Worse than expected
NYSE
CBT
Cabot CORPCabot Corporation announced a planned leadership transition, with President and CEO Sean Keohane retiring effective September 30, 2026, and Erica McLaughlin appointed as his successor.
NYSE
CBT
Cabot CORPCabot Corporation has entered into a new $1.3 billion unsecured revolving credit agreement, replacing its previous credit lines and providing flexibility for general corporate purposes.
NYSE
CBT
Cabot CORPCabot Corporation announced its second quarter fiscal year 2026 results, reporting diluted EPS of $1.27 and adjusted EPS of $1.61, while also increasing its quarterly dividend by 5%.
NYSE
CBT
Cabot CORPCabot Corporation's annual meeting saw stockholders elect three directors, approve executive compensation, and ratify Deloitte & Touche LLP as auditors.
NYSE
CBT
Cabot CORPCabot Corporation reported first-quarter fiscal year 2026 Adjusted EPS of $1.53, a 13% year-over-year decrease, despite strong performance in its Battery Materials product line and a new multi-year supply agreement with PowerCo SE.
Worse than expected
Quarterly Earnings (10-Q)
NYSE
CBT
Cabot CORPCabot Corporation reported a decline in first-quarter net income and sales, driven by lower volumes and pricing in its Reinforcement Materials segment, despite growth in Performance Chemicals EBIT.
Delay expected
Worse than expected
NYSE
CBT
Cabot CORPCabot Corporation reported a decline in third-quarter net income and sales, primarily driven by reduced volumes and less favorable pricing in its Reinforcement Materials segment, despite improved nine-month results due to reduced foreign exchange losses.
Worse than expected
NYSE
CBT
Cabot CORPCabot Corporation's Q2 fiscal year 2025 saw a decrease in net sales but an increase in net income, driven by Performance Chemicals' strong performance offsetting lower Reinforcement Materials volumes.
NYSE
CBT
Cabot CORPCabot Corporation's Q1 2025 net income attributable to Cabot Corporation increased to $93 million, up from $50 million in Q1 2024, driven by lower foreign exchange losses and higher segment earnings.
Better than expected
Delay expected
NYSE
CBT
Cabot CORPCabot Corporation's Q3 2024 earnings increased significantly year-over-year, driven by higher volumes in both Reinforcement Materials and Performance Chemicals segments.
Better than expected
Delay expected
NYSE
CBT
Cabot CORPCabot Corporation's Q2 2024 earnings increased due to higher segment profits and investment income, despite a slight decrease in revenue.
Better than expected
Annual Reports (10-K)
NYSE
CBT
Cabot CORPCabot Corporation reports a mixed fiscal year 2025 with growth in its Performance Chemicals segment offset by declines in Reinforcement Materials and a higher income tax provision, leading to reduced net income and EPS.
Delay expected
Worse than expected
NYSE
CBT
Cabot CORPCabot Corporation's annual 10-K filing highlights its strategic focus on growth through innovation and sustainability, while navigating environmental regulations and global market dynamics.
Delay expected
Worse than expected
Insider Trading (Form 4)
NYSE
CBT
Cabot CORPCabot Corporation director Raffiq Nathoo has reported a transaction involving phantom stock units, with settlement details outlined.
NYSE
CBT
Cabot CORPCabot Corporation's President and CEO, Sean D. Keohane, reported the acquisition of 83.6823 phantom stock units under the company's supplemental 401(k) plan.
NYSE
CBT
Cabot CORPLisa M. Dumont of Cabot Corp reported a transaction involving phantom stock units, increasing her beneficial ownership.
NYSE
CBT
Cabot CORPCabot Corporation Director Douglas G. Del Grosso acquired phantom stock units under the company's Non-Employee Director's Deferral Plan.
NYSE
CBT
Cabot CORPCabot Corporation's SVP and General Counsel, Karen A. Kalita, reported a transaction involving phantom stock units.
NYSE
CBT
Cabot CORPCabot Corporation director Raffiq Nathoo acquired phantom stock units under the company's Non-Employee Director's Deferral Plan.
Proxy Statements (Def-14A)
NYSE
CBT
Cabot CORPCabot Corporation announces its 2026 Annual Meeting of Stockholders, detailing proposals for director elections, executive compensation, and auditor ratification.
NYSE
CBT
Cabot CORPCabot Corporation announces its 2026 Annual Meeting of Stockholders to be held virtually on March 12, 2026, focusing on director elections, executive compensation advisory vote, and auditor ratification.
Better than expected
NYSE
CBT
Cabot CORPCabot Corporation has announced its 2025 Annual Meeting of Shareholders, scheduled for March 13, 2025, and provided details on how shareholders can vote on key proposals.
NYSE
CBT
Cabot CORPCabot Corporation has announced its 2025 Annual Meeting of Stockholders, scheduled for March 13, 2025, where shareholders will vote on director elections, executive compensation, a new incentive plan, and auditor ratification.
Schedule 13G - Passive Investments
NYSE
CBT
Cabot CORPVanguard Capital Management has reported beneficial ownership of 5.22% of Cabot Corporation's common stock as of March 31, 2026.
NYSE
CBT
Cabot CORPVanguard Portfolio Management has reported beneficial ownership of 3,175,315 shares, representing 6.08% of Cabot Corporation's common stock, as of March 31, 2026.
NYSE
CBT
Cabot CORPThe Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Cabot Corp following an internal realignment.
NYSE
CBT
Cabot CORPWellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting a passive beneficial ownership of 7.8% of Cabot Corporation's common stock as of March 31, 2025.